CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031

Follow these storage commandments: Refrigerator storage (unopened): Keep between 36F-46F Store in original packaging to protect from light Dont freeze (frozen = ruined) Keep away from the freezer compartment Room temperature storage (in-use): Below 86F is your friend Away from direct sunlight Not in your car, bathroom, or other temperature-variable locations Cap on when not in use What Happens If My GLP 1 Gets Warm When your GLP-1 injection gets warm, the protein structure can break down, reducing how well the medication controls your blood sugar and supports weight loss
This process is called gastric emptying, and when it slows down, GLP-1 production speeds up
In clinical trials, diarrhea is a common side effect, occurring in approximately 30% of patients taking Wegovy (semaglutide 2.4 mg) and 19-23% of patients taking Zepbound (tirzepatide), according to FDA prescribing information
NC Medicaid removed obesity coverage October 2025